Connor, Clark & Lunn Investment Management Ltd. Arcutis Biotherapeutics, Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$22 Billion
Q2 2024

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2023 May 09, 2023	BUY	$10.23 - $17.14 $84,939 - $142,313	8,303 Added 7.5%	119,029 $1.31 Million
Q4 2022 Feb 10, 2023	BUY	$13.96 - $20.4 $1.55 Million - $2.26 Million	110,726 New	110,726 $1.64 Million

Others Institutions Holding ARQT

# of Institutions

193

Shares Held

127M

Call Options Held

5.43M

Put Options Held

257K

Jennison Associates LLC

11.6M
Shares

$108 Million
0.07% of portfolio
Suvretta Capital Management, LLC New York, NY

10M
Shares

$93 Million
3.89% of portfolio
Rubric Capital Management LP New York, NY

9.82M
Shares

$91.3 Million
2.7% of portfolio
Frazier Life Sciences Management, L.P. Menlo Park, CA

8.79M
Shares

$81.7 Million
4.82% of portfolio
Black Rock Inc. New York, NY

8.62M
Shares

$80.2 Million
0.0% of portfolio

View Full List

About Arcutis Biotherapeutics, Inc.

Ticker ARQT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,187,500
Market Cap $560M
Description
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...

More about ARQT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account